DK3587579T3 - Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna - Google Patents
Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna Download PDFInfo
- Publication number
- DK3587579T3 DK3587579T3 DK19171689.3T DK19171689T DK3587579T3 DK 3587579 T3 DK3587579 T3 DK 3587579T3 DK 19171689 T DK19171689 T DK 19171689T DK 3587579 T3 DK3587579 T3 DK 3587579T3
- Authority
- DK
- Denmark
- Prior art keywords
- catenin
- beta
- compositions
- double
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36177610P | 2010-07-06 | 2010-07-06 | |
| EP16155285.6A EP3037538B1 (en) | 2010-07-06 | 2011-07-01 | Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3587579T3 true DK3587579T3 (da) | 2021-04-26 |
Family
ID=45441761
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11804230.8T DK2591105T3 (da) | 2010-07-06 | 2011-07-01 | Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna |
| DK19171689.3T DK3587579T3 (da) | 2010-07-06 | 2011-07-01 | Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna |
| DK16155285.6T DK3037538T3 (da) | 2010-07-06 | 2011-07-01 | Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11804230.8T DK2591105T3 (da) | 2010-07-06 | 2011-07-01 | Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16155285.6T DK3037538T3 (da) | 2010-07-06 | 2011-07-01 | Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US8815825B2 (da) |
| EP (4) | EP2591105B1 (da) |
| JP (1) | JP5976643B2 (da) |
| AU (1) | AU2011276365B2 (da) |
| CA (2) | CA2804214C (da) |
| DK (3) | DK2591105T3 (da) |
| ES (3) | ES2873893T3 (da) |
| HK (1) | HK1227054A1 (da) |
| PT (1) | PT3587579T (da) |
| WO (1) | WO2012006243A2 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013208720A1 (en) * | 2012-01-09 | 2014-07-24 | Arrowhead Research Corporation | RNAi agents to treat Beta-Catenin related diseases |
| CA2978450A1 (en) * | 2015-03-04 | 2016-09-09 | The University Of Chicago | Beta-catenin inhibitors in cancer immunotherapy |
| AU2017232496B2 (en) | 2016-03-16 | 2022-11-24 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| MA45469A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de bêta-caténine et leurs utilisations |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| CN110461362A (zh) * | 2017-03-28 | 2019-11-15 | 迪克纳制药公司 | 减少β-连环蛋白表达以加强免疫疗法 |
| US10407681B2 (en) * | 2017-03-28 | 2019-09-10 | The United States Of America, As Represented By The Secretary Of Agriculture | Plant-mediated silencing of a fatty acid and retinoid binding protein in Pratylenchus penetrans |
| EP3672980A4 (en) * | 2017-10-18 | 2021-06-16 | Dicerna Pharmaceuticals, Inc. | BETA-CATENIN NUCLEIC ACID INHIBITOR MOLECULE |
| WO2019100039A1 (en) * | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| WO2019136157A2 (en) * | 2018-01-05 | 2019-07-11 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and ido expression to potentiate immunotherapy |
| EP3740248A4 (en) | 2018-03-02 | 2022-01-26 | Dicerna Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEALTH CONDITIONS ASSOCIATED WITH BILE DUCT DEPLETION |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| IL309905A (en) * | 2021-07-23 | 2024-03-01 | Alnylam Pharmaceuticals Inc | IRNA compositions in β-catenin (CTNNB1) and methods of using them |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| PL169576B1 (pl) | 1990-10-12 | 1996-08-30 | Max Planck Gesellschaft | Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US6326487B1 (en) | 1995-06-05 | 2001-12-04 | Aventis Pharma Deutschland Gmbh | 3 modified oligonucleotide derivatives |
| US6218108B1 (en) | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
| US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
| US20060019917A1 (en) * | 2001-05-18 | 2006-01-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
| US20090012018A1 (en) * | 2004-09-13 | 2009-01-08 | Matthias Hebrok | Inhibition of pancretic cancer cell growth |
| US20090176725A1 (en) * | 2005-08-17 | 2009-07-09 | Sirna Therapeutics Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2007031091A2 (en) * | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| DK2152879T3 (da) * | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
| EP2176412B1 (en) * | 2007-06-15 | 2017-09-13 | Beth Israel Deaconess Medical Center | Bacterial mediated tnf-alpha gene silencing |
| TWI455944B (zh) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| JP2012005734A (ja) | 2010-06-28 | 2012-01-12 | Panasonic Corp | 電気掃除機用吸込具及びそれを備えた電気掃除機 |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
-
2011
- 2011-07-01 CA CA2804214A patent/CA2804214C/en active Active
- 2011-07-01 WO PCT/US2011/042820 patent/WO2012006243A2/en active Application Filing
- 2011-07-01 ES ES19171689T patent/ES2873893T3/es active Active
- 2011-07-01 ES ES16155285T patent/ES2734743T3/es active Active
- 2011-07-01 DK DK11804230.8T patent/DK2591105T3/da active
- 2011-07-01 EP EP11804230.8A patent/EP2591105B1/en active Active
- 2011-07-01 AU AU2011276365A patent/AU2011276365B2/en active Active
- 2011-07-01 ES ES11804230.8T patent/ES2635388T3/es active Active
- 2011-07-01 EP EP19171689.3A patent/EP3587579B1/en active Active
- 2011-07-01 PT PT191716893T patent/PT3587579T/pt unknown
- 2011-07-01 DK DK19171689.3T patent/DK3587579T3/da active
- 2011-07-01 DK DK16155285.6T patent/DK3037538T3/da active
- 2011-07-01 EP EP16155285.6A patent/EP3037538B1/en active Active
- 2011-07-01 JP JP2013518762A patent/JP5976643B2/ja active Active
- 2011-07-01 CA CA3146952A patent/CA3146952A1/en active Pending
- 2011-07-01 EP EP21154097.6A patent/EP3854874A1/en not_active Withdrawn
-
2012
- 2012-12-18 US US13/718,525 patent/US8815825B2/en active Active
-
2014
- 2014-06-10 US US14/300,754 patent/US9243244B2/en active Active
-
2015
- 2015-10-28 US US14/925,952 patent/US9428752B2/en active Active
-
2016
- 2016-03-08 US US15/064,376 patent/US10072263B2/en active Active
- 2016-12-20 HK HK16114459A patent/HK1227054A1/zh unknown
-
2018
- 2018-07-09 US US16/030,253 patent/US10612023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3587579T3 (da) | Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna | |
| DK3199165T3 (da) | Fremgangsmåder og sammensætninger til specifik hæmning af kras med asymmetrisk dobbeltstrenget rna | |
| SMT201600291B (it) | Inibitori di proteasi hcv | |
| DK3597749T3 (da) | Fremgangsmåder og sammensætninger til rna-dirigeret mål-dna-modificering og til rna-dirigeret modulering af transkription | |
| DK2914741T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet | |
| DK3208269T3 (da) | Inhibitorer af c-fms-kinase | |
| DK2271642T3 (da) | Pyridylinhibitorer af hedgehog signalering | |
| DK2398794T3 (da) | Hæmmere af hepatitis C-virus | |
| DK3272879T3 (da) | Transposonendesammensætninger og fremgangsmåder til modificering af nukleinsyrer | |
| DK2768321T3 (da) | Fremgangsmåder og sammensætninger til induktion af mæthed | |
| DK2776567T3 (da) | Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. | |
| DK2791367T3 (da) | Mutante mikroorganismer til syntetisering af colansyre, mannosylerede og/eller fucosylerede oligosaccharider | |
| DK3581654T3 (da) | Fremgangsmåder og sammensætninger tiil specifik hæmning af glycolatoxidase (hao1) ved hjælp af dobbeltstrenget rna | |
| DK3428290T3 (da) | Sammensætninger og fremgangsmåder til amplifikation af nukleinsyrer | |
| DOP2012000114A (es) | Inhibidor bromodominio de benzodiazepina | |
| DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
| DK2325648T3 (da) | Fremgangsmåde til detektering af cancer | |
| IL224369B (en) | Combinations of inhibitors for hepatitis c virus | |
| DK2293816T3 (da) | Fremgangsmåder til behandling af reumatoid arthritis | |
| DK3412687T3 (da) | Fremgangsmåder til behandling af dlbcl | |
| DK3109326T3 (da) | Sammensætning og fremgangsmåde til nukleinsyresyntese og amplifikation under anvendelse af rt | |
| DK2598500T3 (da) | Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen | |
| BR112013012319A2 (pt) | inibidores de micro rna compreendendo nucleotídeos bloqueados | |
| DK2793895T3 (da) | Fremgangsmåder og sammensætninger til reducering af kropsfedt og adipocytter | |
| DK2533761T3 (da) | Fremgangsmåder og sammensætninger til fremstilling af aerosoler |